

Opioid-induced bowel dysfunction in cancer-related pain: Causes, consequences, and a novel approach for its management
Abstract
Keywords
References
Ballantyne JC: Opioid analgesia: Perspectives on right use and utility. Pain Physician. 2007; 10: 479-491.
Coluzzi F, Pappagallo M: Opioid therapy for chronic noncancer pain: Practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol. 2005; 71: 425-433.
Choi YS, Billings JA: Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002; 24: 71-90.
Kurz A, Sessler DI: Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs. 2003; 63: 649-671.
European Pain in Cancer (EPIC) Survey: Available at http://www.paineurope.com. Accessed November 2007.
Colvin L, Forbes K, Fallon M: Difficult pain. Br Med J (Clin Res Ed). 2006; 332: 1081-1083.
Pappagallo M: Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182: 11S-18S.
Fitzgibbon DR: Clinical use of opioids for cancer pain. Curr Pain Headache Rep. 2007; 11: 251-258.
Coluzzi F, Mattia C: Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005; 71: 451-460.
Gallego AO, Barón MG, Arranz EE: Oxycodone: A pharmacological and clinical review. Clin Transl Oncol. 2007; 9: 298-307.
Ross FB, Smith MT: The intrinsic antinociceptive effects of oxycodone appear to be [kappa]-opioid receptor mediated. Pain. 1997; 73: 151-157.
Bruera E, Belzile M, Pituskin E, et al.: Randomized, doubleblind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998; 16: 3222-3229.
Mucci-LoRusso P, Berman BS, Silberstein PT, et al.: Controlledrelease oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain. 1998; 2: 239-249.
Lauretti GR, Oliveira GM, Pereira NL: Comparison of sustained-release morphine with sustained release oxycodone in advanced cancer patients. Br J Cancer. 2003; 89: 2027-2030.
Hale ME, Fleischmann R, Salzman R, et al.: Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999; 15: 179-183.
Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology. 2003; 60: 927-934.
Kampe S, Warm M, Kaufmann J, et al.: Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Curr Med Res Opin. 2004; 20: 199-202.
Watson CP, Moulin D, Watt-Watson J, et al.: Controlledrelease oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain. 2003; 105: 71-78.
Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology. 1998; 50: 1837-1841.
Reid CM, Martin RM, Sterne JA, et al.: Oxycodone for cancerrelated pain: Meta-analysis of randomized controlled trials. Archiv Intern Med. 2006; 166: 837-843.
Davis MP: The opioid bowel syndrome: A review of pathophysiology and treatment. J Opioid Manag. 2005; 1: 153-161.
Holzer P: Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004; 361: 192-195.
De Luca A, Coupar IM: Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996; 69: 103-115.
McMillan SC: Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004; 11: 3-9.
Bell T, Milanova T, Grove G, et al.: Obd symptoms impair quality of life and daily activities, regardless of frequency and duration of opioid treatment: Results of a us patient survey (probe survey). J Pain. 2007; 8: S71 (Abstract 882).
Ueberall MA, Mueller-Schwefe G: Opioid-induced constipation–A frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain. 2006; 10: S172.
Moulin DE, Iezzi A, Amireh R, et al.: Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996; 347: 143-147.
Allan L, Hays H, Jensen N-H, et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer. Br Med J (Clin Res Ed). 2001; 322: 1154-1158.
Cook S, Bell T, Sweeney C, et al.: Impact on quality of life of constipation-associated gi symptoms related to opioid treatment in chronic pain patients: Pac-qol results from the opioid survey. J Pain. 2007; 8: S71 (Abstract 883).
Annunziata K, Bell T: Impact of opioid-induced constipation on healthcare resource utilisation and patient functioning. Eur J Pain. 2006; 10: S172 (Abstract 659).
Bell T, Annunziata K, Freedman D, et al.: Opioid-induced constipation increases healthcare resource use and impairs work productivity: Comparison with other patient groups with and without constipation. J Pain. 2007; 8: S75 (Abstract 897).
Ahmedzai SH, Boland J: Constipation in people prescribed opioids. BMJ Clin Evid. 2007; 12: 2407.
Sykes NP: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998; 12: 375-382.
Meissner W, Schmidt U, Hartmann M, et al.: Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84: 105-109.
Liu M, Wittbrodt E: Low-dose oral naloxone reverses opioidinduced constipation and analgesia. J Pain Symptom Manage. 2002; 23: 48-53.
Sykes NP: An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996; 10: 135-144.
Yuan CS, Foss JF, O’Connor M, et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA. 2000; 283: 367-372.
Yuan CS, Wei G, Foss JF, et al.: Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002; 300: 118-123.
Paulson DM, Kennedy DT, Donovick RA, et al.: Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction–a 21-day treatment-randomized clinical trial. J Pain. 2005; 6: 184-192.
Portenoy RK, Thomas J, Moehl Boatwright ML, et al.: Subcutaneous methylnaltrexone for the treatment of opioidinduced constipation in patients with advanced illness: A doubleblind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008; 35: 458-468.
Thomas J, Karver S, Cooney GA, et al.: Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358: 2332-2343.
US Food and Drug Administration: FDA approves Entereg to help restore bowel function following surgery. Available at http://www.fda.gov/bbs/topics/NEWS/2008/NEW01838.html. Accessed November 20, 2008.
Saad RJ, Chey WD: Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs. 2008; 17: 117-130.
De Schepper HU, Cremonini F, Park MI, et al.: Opioids and the gut: Pharmacology and current clinical experience. Neurogastroenterol Motil. 2004; 16: 383-394.
Meissner W, Leyendecker P, Mueller-Lissner S, et al.: A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009; 13: 56-64.
Nadstawek J, Leyendecker P, Hopp M, et al.: Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008; 62: 1159-1167.
Vondrackova D, Leyendecker P, Meissner W, et al.: Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008; 9: 1144-1154.
Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 (Suppl 2): 1143-1147.
DOI: https://doi.org/10.5055/jom.2009.0015
Refbacks
- There are currently no refbacks.